TuHURA Biosciences, Inc. Common Stock (HURA) is a publicly traded Healthcare sector company. As of November 4, 2026, HURA trades at $1.68 with a market cap of $109.61M and a P/E ratio of -3.10. HURA moved +0.00% today. Year to date, HURA is +120.81%; over the trailing twelve months it is -34.84%. Its 52-week range spans $0.41 to $4.44. Analyst consensus is buy with an average price target of $9.00. Rallies surfaces HURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TuHURA reports partial responses in first three patients in IFx-2.0–Keytruda trial: TuHURA Biosciences reported preliminary results from a Phase 1b/2a trial of IFx-2.0 with Keytruda in metastatic Merkel cell carcinoma: all three initial patients had substantial tumor shrinkage, with responses ongoing at six months.
| Metric | Value |
|---|---|
| Price | $1.68 |
| Market Cap | $109.61M |
| P/E Ratio | -3.10 |
| EPS | $-0.63 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.44 |
| 52-Week Low | $0.41 |
| Volume | 7.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-30.05M |
| Gross Margin | 0.00% |
2 analysts cover HURA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.00.